Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.
We evaluated the psychological effects of the antiepilepsy drug vigabatrin in a randomized multicenter double-blind placebo-controlled parallel group study that compared 3 grams oral vigabatrin with placebo as daily add-on therapy in patients with focal epilepsy whose complex partial seizures were difficult to control. Testing at baseline and after 12 weeks of vigabatrin (n = 83) or placebo (n = 85) used eight measures of cognitive abilities and three of mood and adjustment. The vigabatrin and placebo groups were highly similar at entry into the study. At the end of the study, there were no differences between the vigabatrin and placebo groups on any cognitive variable or on any measure of mood and adjustment. Analysis of the results related to relief from seizures demonstrated only chance findings. In a similar manner, there were no relationships between vigabatrin serum levels at the end of the study and changes on measures of abilities and adjustment. Vigabatrin appears to be a useful antiepilepsy drug with little impact upon tests of either cognitive abilities or quality of life.
Dodrill
C B
CB
Department of Neurological Surgery, University of Washington School of Medicine, Seattle.
Arnett
J L
JL
Sommerville
K W
KW
Sussman
N M
NM
D000223:Adaptation, Psychological / Q000187:drug effects; D000328:Adult; D000339:Affect / Q000187:drug effects; D000614:Aminocaproates / Q000097:blood / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D004827:Epilepsy / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011788:Quality of Life; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D020888:Vigabatrin